Forward-Looking Statements
The following plan of operation provides information which management believes
is relevant to an assessment and understanding of our results of operations and
financial condition. The discussion should be read along with our financial
statements and notes thereto. This section includes a number of forward-looking
statements that reflect our current views with respect to future events and
financial performance. Certain statements that the Company may make from time to
time, including all statements contained in this report that are not statements
of historical fact, constitute "forward-looking statements". Forward-looking
statements may be identified by words such as "plans," "expects," "believes,"
"anticipates," "estimates," "projects," "will," "should," and other words of
similar meaning used in conjunction with, among other things, discussions of
future operations, financial performance, product development and new product
launches, market position and expenditures. You should not place undue certainty
on these forward-looking statements. These forward-looking statements are
subject to certain risks and uncertainties that could cause actual results to
differ materially from our predictions.
The following Management's Discussion and Analysis of Financial Condition and
Results of Operations ("MD&A") is intended to help you understand our historical
results of operations during the periods presented and our financial condition
for the years ended June 30, 2022 and 2021. This MD&A should be read in
conjunction with our financial statements as of June 30, 2022 and 2021. See
section entitled "Forward-Looking Statements" above.
Overview
We are engaged in pursuing pre-clinical and drug development activities for
certain pharmaceutical formulations that include cannabinoids. We have filed
three provisional patent applications and acquired a license covering certain
intellectual property related to a drug delivery system.
As a relatively new business engaged in start-up operations and activities, we
will require substantial additional funding to successfully complete any of our
drug development programs. At present, we cannot estimate the substantial
capital requirements needed to secure regulatory approvals for our drug
candidates. We estimate that we have sufficient capital to maintain our
existence as a public company for the remainder of the current calendar year.
29
We are a start-up company with no revenues from operations. Notwithstanding our
successful raise of $2,076,158, net of offering costs, in equity capital since
inception to June 30, 2022, and the receipt of $146,750, net of financing costs,
from a debt issuance in January 2022, there is substantial doubt that we can
continue as an on-going business for the next twelve months without a
significant infusion of capital or entering into a business combination
transaction. We do not anticipate that Nexien BioPharma will generate revenues
from its research and development activities related to its drug development
projects in the near future, due to the protracted revenue model of pursuing
pharmaceutical drug development in accordance with the pathway set forth by the
FDA. The Company had to cease research and development activities due to the
lack of sufficient working capital and intends to recommence research and
development activities on its myotonic dystrophy project from the proceeds of
its funding in January 2022. While management continues its efforts to raise
additional capital for the Company, it is also seeking merger or other business
combination or restructuring opportunities.
Results of Operations
Net loss for the year ended June 30, 2022 was $626,357 as compared to the net
loss of $1,859,942 for the year ended June 30, 2021, a decrease of $1,233,185.
As explained below, most of the loss is attributable to significant stock-based
compensation costs, the fair value of common stock issued for the CRx
acquisition, and the fair value of warrants issued in conjunction with
convertible debt financings.
The Company incurred professional fees of $33,230 for the year ended June 30,
2022, a decrease of $10,480 from $43,710 for the year ended June 30, 2021. Fees
for 2022 and 2021 were for SEC regulatory and statutory filings and annual audit
and quarterly review fees to our auditor.
General and administrative costs for the year ended June 30, 2022 of $530,762
includes $155,750 of non-cash stock-based compensation costs for common shares
issued to officers of the Company, $223,255 for the vesting of shares issued to
CRx subject to forfeiture and the fair value of warrants issued in conjunction
with our 2022 third-party convertible debt financing of $110,264. General and
administrative costs of $1,800,057 for the year ended June 30, 2021 includes
$306,250 of non-cash stock-based compensation costs for common shares issued to
officers and directors and the fair value of vested stock options granted of
$348,953. Also included in general and administrative expenses for 2021 is a
non-cash charge of $1,093,667 for the vesting of shares issued to CRx subject to
forfeiture.
Exclusive of stock-based compensation costs, general and administrative costs
for the year ended June 30, 2022 were $41,492 a decrease of $53,403 from the
June 30, 2021 comparable costs of $94,895. The decrease was attributable to cost
containment efforts instituted by the Company to preserve capital.
During the year ended June 30, 2021, the Board of Directors granted options to
purchase a total of 5,000,000 shares of common stock to officers of the Company,
exercisable for a period of seven years at an exercise price of $0.08 per share.
There were no research and development costs incurred for the years ended June
30, 2022 and 2021, due to the Company's limited financial resources and
availability of research personnel.
The Company incurred interest expense of $17,945 and $3,234, respectively,
during the years ended June 30, 2022 and 2021 for interest on debt offerings
during the periods, including $3,625 of imputed interest on advances from the
Company's CEO. At June 30, 2022 and 2021, the Company had outstanding
convertible notes in the principal amounts of $65,000 to its CEO and a
shareholder, and $170,454 to a third party.
During the years ended June 30, 2022 and 2021, the Company incurred $44,420 and
$12,941, respectively, for interest and amortization of discount related to the
convertible debt financings.
Liquidity and Capital Resources
At June 30, 2022, we had a working capital deficit of $117,605 and cash of
$116,898 as compared to a working capital deficit of $13,775 and cash of $18,041
at June 30, 2021. The increase in both working capital and cash was due
primarily to $146,750 in funding from a convertible debt financing received in
January 2022. Substantially all available funds were being utilized solely for
maintaining corporate operations as a public company. During the year ended June
30, 2022, we used $75,143 of cash for operating activities and were provided
cash from financing activities of $174,000. In addition to the receipt of
$146,750 from the convertible debt financing, we also received a
non-interest-bearing advance from our CEO for working capital in the amount of
$25,000, and $2,250 from an exercise of warrants from a third party. During the
year ended June 30, 2021, we used $90,745 of cash for operating activities, and
had increase in liquidity from financing of $98,000 from a convertible debt loan
from our CEO and a major shareholder and a $20,000 advance for operating
activities from our CEO.
30
In November 2020, we issued unsecured convertible promissory notes to our CEO
and a shareholder of the Company in the amounts of $40,000 and $25,000,
respectively, for cash loans made to the Company. The notes are due three years
from issuance and accrue interest at the rate of 8% per annum, compounded
annually. The notes and accrued interest are convertible at the option of the
holders at any time into restricted shares of the Company's common stock at a
price of $0.037631, being the volume-weighted average price of the common stock
over the 10 trading days immediately preceding the date the note was funded.
Both lenders were issued three types of warrants, exercisable for a five-year
period, at prices of $0.040265, $0.043276, and $0.045157, to purchase a total of
5,181,897 shares.
As of June 2022, the Company's Chief Executive Officer has advanced an aggregate
$45,000 to the Company for working capital and operating purposes. The advance
is non-interest bearing and is repayable on demand.
While management of the Company believes that the Company will be successful in
its current and planned activities, there can be no assurance that the Company
will be successful in its drug development activities, and raise sufficient
equity, debt capital or strategic relationships to sustain the operations of the
Company.
Our ability to create sufficient working capital to sustain us over the next
twelve-month period, and beyond, is dependent on our raising additional equity
or debt capital or entering into strategic arrangements with one or more third
parties.
There can be no assurance that sufficient capital will be available to us. We
currently have no agreements, arrangements or understandings with any person to
obtain funds through bank loans, lines of credit or any other sources.
Availability of Additional Capital
Notwithstanding our success in raising gross proceeds of $2.1 million from the
private sale of equity securities through June 30, 2022, and the completion of a
debt financing agreement resulting in the receipt of $146,750 in January 2022,
there can be no assurance that we will continue to be successful in raising
equity capital and/or debt financings and have adequate capital resources to
fund our operations or that any additional funds will be available to us on
favorable terms or in amounts required by us. We estimate that we have
sufficient capital resources to maintain our existence as a public company for
the remainder of the current calendar year.
Any additional equity financing may be dilutive to our stockholders, new equity
securities may have rights, preferences or privileges senior to those of
existing holders of our shares of Common Stock. Debt or equity financing may
subject us to restrictive covenants and significant interest costs.
Capital Expenditure Plan During the Next Twelve Months
To date, we raised approximately $2.1 million, in equity capital (including
exercised warrants) and $146,750 in debt financings. There can be no assurance
that we will continue to be successful in raising capital in sufficient amounts
and/or at terms and conditions satisfactory to the Company. Our revenues are
expected to come from our drug development projects. As a result, we will
continue to incur operating losses unless and until we have obtained regulatory
approval with respect to one of our drug development projects and commence to
generate sufficient cash flow to meet our operating expenses. There can be no
assurance that we will obtain regulatory approval and the market will adopt our
future drugs. In the event that we are not able to successfully: (i) raise
equity capital and/or debt financing; or (ii) market our drugs after obtaining
regulatory approval, our financial condition and results of operations will be
materially and adversely affected.
31
Going Concern Consideration
Our registered independent auditors have issued an opinion on our financial
statements as of June 30, 2022 which includes a statement describing our going
concern status. This means that there is substantial doubt that we can continue
as an on-going business for the next twelve months unless we obtain additional
capital to pay our bills and meet our other financial obligations. This is
because we have not generated any revenues and no revenues are anticipated until
we begin marketing any drugs that we successfully develop. Accordingly, we must
raise capital from sources other than the actual sale from any drugs that we
develop. We must raise capital to continue our drug development activities and
stay in business.
Off-Balance Sheet Arrangements
At June 30, 2022 and 2021, we did not have any off-balance sheet arrangements as
defined in Item 303(a)(4)(ii) of Regulation S-K promulgated under the Securities
Act of 1934.
Contractual Obligations and Commitments
In February 2018, we obtained a worldwide exclusive license with respect to a
proprietary delivery system for cannabinoid-based medications. Under the terms
of the license agreement, we paid $65,000 in cash and issued common stock of the
Company, valued at $35,000, to the licensor. We are required to pay milestone
payments upon obtaining regulatory approval of pharmaceutical licensed products
and royalties based upon sales of licensed products. We may grant sublicenses
under the terms of the agreement. We previously estimated that we may not be
able to recover the costs capitalized under the license agreement and recognized
an impairment of the amounts paid. Although we have recognized an impairment
under Generally Accepted Accounting Principles, we retain our rights under the
license agreement.
Critical Accounting Policies
Our significant accounting policies are described in the notes to our financial
statements as of June 30, 2022 and 2021 and are included elsewhere in this
report.
© Edgar Online, source Glimpses